NewLab joins Charles River Biopharmaceutical Services, which provides services to support the development and manufacture of biologics.
James Foster, chairman, president and CEO of Charles River, said: “The acquisition of NewLab further strengthens our portfolio of essential products and services to help our clients accelerate drug development.
“NewLab enhances the scientific depth, geographic scope and client base of Charles River’s global biopharmaceutical services offering to support the rapidly growing market for biologic drug compounds.”